Source: Healio News
Approximately one-quarter of patients with hematologic malignancies did not produce measurable antibodies after two doses of COVID-19 vaccines, according to a study from The Leukemia & Lymphoma Society published in Cancer Cell.
Results varied depending on blood cancer type. Patients with non-Hodgkin lymphoma appeared least likely to develop antibody protection, and patients with multiple myeloma had the highest level of antibodies following vaccination.
“Patients who fail to make antibodies in response to the SARS-CoV-2 vaccines may be vulnerable to COVID-19 breakthrough infections